Nerandomilast appears to reduce the risk of death in people with IPF and PPF, according to analyses of clinical trial data.

Ingelheim, Germany/Ridgefield, Connecticut, U.S.Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in ...

The FDA has approved Boehringer Ingelheim's nerandomilast as a treatment for idiopathic pulmonary fibrosis (IPF), giving the ...

UVA Health lung researchers are developing a promising approach to detecting patients at risk of interstitial lung disease ...

The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim Jascayd (nerandomilast) tablets to treat ...

Jascayd targets the enzyme PDE4B, which plays a role in the inflammatory process. The new therapy is able to affect both fibrosis and the immune system. It will be available in the next few weeks.

FDA approves Jascayd, the first new treatment for idiopathic pulmonary fibrosis in over a decade, significantly reducing ...

CHICAGO, Sept. 2, 2025 /PRNewswire/ -- September is Pulmonary Fibrosis Awareness Month, and the American Lung Association today announced a new educational program to help people living with pulmonary ...

Researchers at UVA Health are working on a new way to detect a serious lung disease before it becomes dangerous. The disease, ...

Ingelheim, Germany Friday, October 10, 2025, 09:00 Hrs [IST] ...

EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trialTrial will evaluate ...